Swiss National Bank Anavex Life Sciences Corp. Transaction History

Swiss National Bank

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 06, 2024	SELL	$5.04 - $9.95 $81,648 - $161,190	-16,200 Reduced 9.12%	161,500 $1.5 Million
Q3 2023 Nov 08, 2023	BUY	$6.55 - $9.37 $28,820 - $41,228	4,400 Added 2.54%	177,700 $1.16 Million
Q2 2023 Aug 09, 2023	BUY	$7.66 - $9.5 $38,300 - $47,500	5,000 Added 2.97%	173,300 $1.41 Million
Q1 2023 May 10, 2023	SELL	$8.32 - $11.75 $165,568 - $233,825	-19,900 Reduced 10.57%	168,300 $1.44 Million
Q4 2022 Feb 08, 2023	BUY	$7.65 - $14.43 $35,190 - $66,378	4,600 Added 2.51%	188,200 $1.74 Million
Q3 2022 Nov 09, 2022	BUY	$8.9 - $12.86 $36,490 - $52,726	4,100 Added 2.28%	183,600 $1.9 Million
Q2 2022 Aug 09, 2022	BUY	$7.31 - $12.84 $63,597 - $111,708	8,700 Added 5.09%	179,500 $1.8 Million
Q1 2022 May 09, 2022	BUY	$9.74 - $17.69 $122,724 - $222,894	12,600 Added 7.96%	170,800 $2.1 Million
Q4 2021 Feb 08, 2022	BUY	$16.88 - $23.31 $195,808 - $270,396	11,600 Added 7.91%	158,200 $2.74 Million
Q2 2021 Aug 06, 2021	BUY	$10.16 - $28.86 $1.49 Million - $4.23 Million	146,600 New	146,600 $3.35 Million

163

27.5M

515K

838K

Ticker AVXL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,942,800
Market Cap $673M
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

Stay updated on Swiss National Bank with notifications on news.